Clinical trial
A Study in People With Abnormal Fat Levels in the Blood
NCT00116519 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00116519 |
|---|---|
| Title | A Study in People With Abnormal Fat Levels in the Blood |
| Official title | PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dyslipidemia |
| Intervention type | Drug |
| Interventions | PPAR alpha, placebo |
| Enrollment | 300 |
| Start date | Jul 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Jun 30, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: